OmniAb, Inc. (OABI)
OmniAb, Inc. (OABI) from its SEC filings: 2025 revenue $18.7 million (-29% vs the year before), net margin -347%, free cash flow -$37.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Commercial Physical & Biological Research |
| Revenue (2025) | $18.7 million |
| Revenue growth | -29% |
| Net income | -$64.8 million |
| Net margin | -347.0% |
| Free cash flow | -$37.0 million |
| Diluted EPS | $-0.57 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +244% |
| Cash | $24.3 million |
| Share count, 1 year | +18% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.